WHO ICTRP trial
PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early…
NL-OMON22681 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON22681 |
|---|---|
| Public title | PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early disease phase |
| Scientific title | PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early disease phase, a multicenter trial |
| Primary sponsor | Sint Maartenskliniek Nijmegen |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Conditions | polymyalgia rheumatica (PMR) spierreuma Jylamvo Methotrexate;10003816;Jylamvo;Methotrexate |
| Interventions | Patienten zullen gerandomiseerd worden met een 1:1 ratio voor behandeling met MTX (25mg/week na een opbouw periode van 15mg/week voor 4 weken) of placebo gedurende 52 weken. Alle patiënten krijgen foliumzuur 10mg/week en prednison, initieel… |
| Registration date | Feb 10, 2020 |
| Target size | 100 |
| Secondary IDs | NL8366;2019-002413-18;NL69979.091.19 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: